Grobben M, Bakker M, Schriek A, Levels L, Umotoy J, Tejjani K
PLoS Pathog. 2024; 20(12):e1012739.
PMID: 39661636
PMC: 11634010.
DOI: 10.1371/journal.ppat.1012739.
Chan W, He B, Wang X, He M
Genes Dis. 2020; 7(4):502-519.
PMID: 32837984
PMC: 7340039.
DOI: 10.1016/j.gendis.2020.07.001.
Crowley A, Ackerman M
Front Immunol. 2019; 10:697.
PMID: 31024542
PMC: 6463756.
DOI: 10.3389/fimmu.2019.00697.
Smith S, Burton S, Kilembe W, Lakhi S, Karita E, Price M
Front Immunol. 2019; 9:3163.
PMID: 30697215
PMC: 6341001.
DOI: 10.3389/fimmu.2018.03163.
Forthal D, Finzi A
AIDS. 2018; 32(17):2439-2451.
PMID: 30234611
PMC: 6497078.
DOI: 10.1097/QAD.0000000000002011.
Conformational Masking and Receptor-Dependent Unmasking of Highly Conserved Env Epitopes Recognized by Non-Neutralizing Antibodies That Mediate Potent ADCC against HIV-1.
Lewis G, Finzi A, DeVico A, Pazgier M
Viruses. 2015; 7(9):5115-32.
PMID: 26393642
PMC: 4584300.
DOI: 10.3390/v7092856.
Role of Fc-mediated antibody function in protective immunity against HIV-1.
Lewis G
Immunology. 2014; 142(1):46-57.
PMID: 24843871
PMC: 3992047.
DOI: 10.1111/imm.12232.
Activation of NK cells by HIV-specific ADCC antibodies: role for granulocytes in expressing HIV-1 peptide epitopes.
Madhavi V, Navis M, Chung A, Isitman G, Wren L, De Rose R
Hum Vaccin Immunother. 2013; 9(5):1011-8.
PMID: 23324623
PMC: 3899135.
DOI: 10.4161/hv.23446.
A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1- or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assays.
Alpert M, Heyer L, Williams D, Harvey J, Greenough T, Allhorn M
J Virol. 2012; 86(22):12039-52.
PMID: 22933282
PMC: 3486484.
DOI: 10.1128/JVI.01650-12.
ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge.
Alpert M, Harvey J, Lauer W, Reeves R, Piatak Jr M, Carville A
PLoS Pathog. 2012; 8(8):e1002890.
PMID: 22927823
PMC: 3426556.
DOI: 10.1371/journal.ppat.1002890.
Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding.
Smalls-Mantey A, Doria-Rose N, Klein R, Patamawenu A, Migueles S, Ko S
J Virol. 2012; 86(16):8672-80.
PMID: 22674985
PMC: 3421757.
DOI: 10.1128/JVI.00287-12.
The role of natural killer (NK) cells and NK cell receptor polymorphisms in the assessment of HIV-1 neutralization.
Brown B, Wieczorek L, Kijak G, Lombardi K, Currier J, Wesberry M
PLoS One. 2012; 7(4):e29454.
PMID: 22509241
PMC: 3324450.
DOI: 10.1371/journal.pone.0029454.
Antibody-Mediated Fcγ Receptor-Based Mechanisms of HIV Inhibition: Recent Findings and New Vaccination Strategies.
Holl V, Peressin M, Moog C
Viruses. 2011; 1(3):1265-94.
PMID: 21994593
PMC: 3185537.
DOI: 10.3390/v1031265.
B cell depletion in HIV-1 subtype A infected Ugandan adults: relationship to CD4 T cell count, viral load and humoral immune responses.
Oballah P, Flach B, Eller L, Eller M, Ouma B, de Souza M
PLoS One. 2011; 6(8):e22653.
PMID: 21886768
PMC: 3160298.
DOI: 10.1371/journal.pone.0022653.
Activation of NK cells by ADCC antibodies and HIV disease progression.
Chung A, Navis M, Isitman G, Wren L, Silvers J, Amin J
J Acquir Immune Defic Syndr. 2011; 58(2):127-31.
PMID: 21792067
PMC: 3175260.
DOI: 10.1097/QAI.0b013e31822c62b9.
Fc receptor-mediated antiviral antibodies.
Forthal D, Moog C
Curr Opin HIV AIDS. 2010; 4(5):388-93.
PMID: 20048702
PMC: 2882066.
DOI: 10.1097/COH.0b013e32832f0a89.
Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection.
Ahmad R, Sindhu S, Toma E, Morisset R, Vincelette J, Menezes J
J Clin Immunol. 2001; 21(3):227-33.
PMID: 11403230
DOI: 10.1023/a:1011087132180.
The Role of the Envelope Glycoprotein in the Depletion of T Helper Cells in Human Immunodeficiency Virus Infection.
Jassoy C, Heinkelein M, Sopper S
Pathol Oncol Res. 1997; 3(1):62-67.
PMID: 11173628
DOI: 10.1007/BF02893356.
Deficient antibody-dependent cellular cytotoxicity against human immunodeficiency virus (HIV)-expressing target cells in perinatal HIV infection.
Ziegner U, Campbell D, Weinhold K, Frank I, Rutstein R, Starr S
Clin Diagn Lab Immunol. 1999; 6(5):718-24.
PMID: 10473524
PMC: 95761.
DOI: 10.1128/CDLI.6.5.718-724.1999.
Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro.
Oliva A, Kinter A, Vaccarezza M, Rubbert A, Catanzaro A, Moir S
J Clin Invest. 1998; 102(1):223-31.
PMID: 9649576
PMC: 509084.
DOI: 10.1172/JCI2323.